| INTRODUC TI ON
The epidemiology of yeast infections and fungemia continues to evolve throughout the world, in parallel with advances in medical care for critically ill and immunocompromised patients and the extensive use of antifungal agents. [1] [2] [3] [4] [5] Among human fungal pathogens, Candida species are the most common yeast that cause bloodstream
infections. In the majority of guidelines, echinocandins are the recommended first-line therapy for candidemia, due to their clinical efficacy, fungicidal activity, favourable safety profile, and limited drug interactions, and concerns about fluconazole resistance. [6] [7] [8] [9] [10] [11] Among non-Candida yeast, Cryptococcus is the most common fungal pathogen that causes community-acquired invasive fungal disease and is intrinsically resistant to echinocandins. 4, 12, 13 In Taiwan, the proportion of Cryptococcus neoformans from blood or bone marrow increased from 14% (8/59) between 1957 and 1972 to 33% (29/87) between 1982 and 1997. 14 In addition, the emergence of rare yeast species such as Trichosporon and Rhodotorula poses a major threat because of their low susceptibility and potential to develop resistance to one or more antifungal agents. 4, 12, 13, 15 Overall, common human yeast pathogens known to be intrinsically resistant or non-susceptible to echinocandins (echinocandin non-susceptible yeast, ENSY), including Cryptococcus, Geotrichum, Malassezia, Pseudozyma, Rhodotorula, Saprochaete, Sporobolomyces and Trichosporon. 4, 12, [15] [16] [17] Species identification is therefore important in order to target echinocandin therapy only at patients with susceptible yeast infections. However, it usually takes an additional 1-3 days to identify yeast to species level using either manual methods or commercially available API ID32C, AuxaColor and Vitek 2 systems. 18, 19 This delay in identification means that, in some cases, inappropriate echinocandin therapy may be initiated in patients with reported yeast isolation from blood. This underlines the limits of presumptive treatment for fungemia and stresses the necessity to introduce rapid identification methods for yeast species identification. 19 However, it is concerning that in a recent survey of mycology laboratory practice across seven Asian countries, rapid identification methods such as matrix-assisted laser desorption ionisation-time of flight mass spectrometry, and molecular identification methods such as PCR and sequencing were available only in 27 laboratories (12.3%) and 37 (16.9%) among 219 respondents, respectively. 20 Most laboratories that perform identification with MALDI still require a subculture, which delays identification by 1 to 3 days (especially for slower growing basidiomycetous yeast). The potential impact of presumptive treatment with echinocandins for fungemia remains uncertain.
The aim of the current collaborative study was to determine the frequency of isolation from blood of yeast species that are intrinsically resistant or non-susceptible to echinocandins. The study was based on laboratory-based surveillance at 25 hospitals located in six Asian countries/regions. 21 We also reviewed and compared published data around the world. (17), manual assimilation/fermentation tests (6) and automatic methods (such as Vitek) (12) .
| MATERIAL S AND ME THODS

| Study design and mycology data collection
Only four hospitals provided the molecular identification methods such as PCR and sequencing in routine practice during the study period.
The data recorded for each isolate included the date of collection, hospital service, genus and species, whenever available. Duplicates were removed from the analysis. Yeast isolates were considered to be duplicate if they came from the same source type in the same patient, within 7 days of each other, and the final identifications were the same. 22 The frequencies of ENSY among non-duplicate yeast isolated from blood cultures were analysed; these included 
| Statistical analysis
Statistical analyses were performed using SPSS v19 (SPSS Inc., Chicago, IL, USA). Categorical variables were analysed using the chisquare test, and continuous variables were compared by Student's t-test. A P-value < 0.05 was considered to be statistically significant. 
| RE SULTS
| Fungal isolates
| Genus distribution by country/region
The proportions of ENSY among yeast-in-blood isolates (overall, 146/2155, 6.7%) from each country/region are shown in Figure 1 . ENSY proportions in most country/region are below Cryptococcus spp. were most frequently observed in Thailand (20.2% of 173 yeast-in-blood isolates) but were rare in India (0.6% of 341 isolates) ( Figure 1 ). A total of 23 Trichosporon isolates were reported, of which 11 were from Taiwan and four were from China. Among 10 Rhodotorula isolates, eight were reported from Taiwan.
| Species distribution according to medical services
Among the 2155 yeast-in-blood isolates included in this analysis, information on the type of medical service from which they came were available for 2144 isolates. Of the 11 isolates for which medical service information was not available, three were ENSY. Thus, 143
ENSY were analysed according to medical service. Overall, almost two-thirds (59.4%) of ENSY came from general wards other than haematology-oncology units (Figure 2A ).
However, this was largely because most yeast isolates overall came from these wards. When analysed according to each different type of medical service, the proportion of total isolates that were ENSY varied substantially, ranging from 2.9%
in haematology-oncology wards to 25.0% in outpatient clinics ( Figure 2B ). 
| Species distribution by season
Based on the date provided, the season of collection could be assigned to each isolate. The proportion of ENSY varied from 4.2% in F I G U R E 1 Distribution within each country/region of 146 yeast isolated from blood and bone marrow specimens that were intrinsically resistant or had a high probability of non-susceptibility to echinocandins. HK, Hong Kong F I G U R E 2 Proportion of the total number of 143 yeast isolated from blood and bone marrow specimens that were intrinsically resistant or had a high probability of non-susceptibility to echinocandins coming from each hospital service (A). Distribution within each medical service of yeast that were intrinsically resistant or had a high probability of non-susceptibility to echinocandins (B). "Other wards" included general wards other than those specialising in haematology-oncology. ER, emergency rooms; Hema, haematology-oncology ward; ICU, intensive care unit; OPD, outpatient clinic autumn to 8.2% in winter, but these differences were not statistically significant. The proportions of individual species (Cryptococcus, Trichosporon and Rhodotorula) also did not vary substantially according to season, which was either due to small sample sizes or variations between countries ( Figure S1 ).
| D ISCUSS I ON
In this 1-year surveillance study conducted in 25 hospitals across Asia, yeast that were intrinsically resistant or non-susceptible to echinocandins accounted for 6.7% of 2155 non-duplicate isolates from the blood. The frequency varied from 2.9% in haematologyoncology wards to 25.0% in outpatient clinics.
Most non-Candida yeast are known to be resistant to echinocandins; 4 and indeed, this study showed that 83.4% of such isolates were ENSY. Hence, it is clinically significant that non-Candida yeast accounted for 8.1% of all yeast-in-blood isolates (Table 1) .
Moreover, proportions varied substantially between the six countries/regions included in the survey, with non-Candida species making up 24.9% of isolates from Thailand but only 2.3% of those from
India. This wide variation in the proportion of non-Candida species accords with other reports from around the world (summarised in Table 2 ). Overall, frequencies were higher in tropical countries, such
as Mexico, Brazil and Thailand. [23] [24] [25] Our study also showed similar results. (Figure 2 )
In the present study, Cryptococcus was the predominant ENSY species. Cryptococcus is the leading ENSY pathogen in many countries worldwide (Table 2) , although there are exceptions. For example, in Belgium and Denmark, Saccharomyces cerevisiae were the predominant non-Candida isolates. 26, 27 Higher proportions of
Cryptococcus in blood are closely related to human immunodeficiency diseases. 23, 28, 29 The proportions of non-Candida yeast varied from 1.0% to 34% in different countries, patient papulations and medical settings ( Table 2 ). In our study, almost a quarter of non-Candida yeast occurred in the outpatient clinics or ERs, which may explain the difference between hospital-based studies and inpatient-only studies (Table 2) .
Not all yeast are susceptible to echinocandins. 4, 12, 13, 15, 17 Furthermore, there are currently no guidelines or recommendations that explicitly describe how to select appropriate presumptive therapy for fungemia in regions where rapid identification systems are not available and non-Candida yeast-in-blood is common. Physicians in these countries should be familiar with common presentations and risk factors associated with Cryptococcus and other non-Candida infections (Table S1) review and comments during preparation, and had final responsibility for the decision to submit for publication.
